glp-1 for metabolic syndrome Agonists - What is it? What I love about GLP-1s

Key Findings: Large human studies across multiple countries have not found increased thyroid cancer rates in GLP-1 users The FDA warning applies to medullary thyroid carcinoma (MTC)only 3-4% of all thyroid cancers The warning exists because rodents developed C-cell tumors, but humans and rodents differ biologically Some studies show associations, but these are explained by detection bias (more monitoring = finding pre-existing nodules) The Clayman Thyroid Center (2,000+ thyroid cancer patients/year) has not seen an MTC pattern linked to GLP-1 use (or for that matter any other thyroid malignancy) Clinical Recommendations: Patients with MTC history or MEN2 should not take GLP-1 receptor agonists Patients with common thyroid cancers (papillary, follicular, Hrthle cell) should not assume GLP-1 caused them or will have an effect upon them Decisions should be individualized, weighing metabolic benefits against theoretical concerns GLP-1 therapy does not require additional thyroid monitoring Quick Reference for Clinicians Understanding the Question What Medications Are We Discussing

As such, exenatide was employed in small-scale, proof of concept, human trials in PD patients, with these trials of 3.0.CO;2-G177 164 PorterWDFlattPRHlscherCGaultVA

Knockdown of GLP1 receptors within the CNS also failed to alter baseline blood glucose levels (Table 2), supporting a principal action for GLP1 in the periphery for proper basal glycaemic control (Sisley et al., 2014)

JRNYS does not accept or bill insurance directly

However, exendin-4 does not change the membrane potential as well as the firing rate of melanin-concentrating hormone (MCH) neurons in the lateral hypothalamus (Acuna-Goycolea and van den Pol, 2004)